Latest / The Well-Built Life / CRISPR Revolution: One-Dose Treatment for Cardiovascular Health
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. All right, let's dive into CTX 310.
- 0:27Speaker 1: The one dose therapy that's making waves in the world
- 0:29Speaker 1: of genetic medicine. Who would? They thought we could target
- 0:33Speaker 1: an NBTL3 gene to reduce LDL cholesterol so effectively.
- 0:38Speaker 2: Indeed, it's a groundbreaking approach. From what I have read,
- 0:42Speaker 2: the initial results from the Cleveland Clinic trial are nothing
- 0:45Speaker 2: short of impressive. They targeted 15 participants with high-risk lipid
- 0:51Speaker 2: disorders that hadn't responded to conventional treatments. Can you elaborate
- 0:56Speaker 2: a bit more on how they achieved these reductions in
- 0:59Speaker 2: LDL cholesterol? Sure.
- 1:01Speaker 1: The treatment uses CRISPR technology to introduce a genetic change
- 1:05Speaker 1: that mimics natural variants linked to lower LDL levels. Essentially,
- 1:10Speaker 1: they are editing the ANPTL3 gene to reduce its expression. Interestingly,
- 1:14Speaker 1: four participants who received the highest dose saw a 78.6%
- 1:18Speaker 1: reduction in ANKETL3 levels. which correlates to significant drops in
- 1:24Speaker 1: LDL cholesterol and triglycerides.
- 1:26Speaker 2: That's a remarkable success rate. But let's back up a bit.
- 1:30Speaker 2: Why ANG-PTL-3 and why CRISPR? The NAGEM publication notes the
- 1:35Speaker 2: unique opportunity in targeting hepatocytes. Do you think this approach
- 1:40Speaker 2: could be a game changer for chronic conditions like high cholesterol?
- 1:44Speaker 1: Potentially, yes. The one-time nature of the treatment is a
- 1:48Speaker 1: big plus, especially considering the cumbersome, and often lifelong nature
- 1:53Speaker 1: of current pharmacological interventions. It's like turning a chronic condition
- 1:58Speaker 1: into a one-and-done scenario, but let's not forget, this is
- 2:03Speaker 1: still very much at the experimental stage.
- 2:05Speaker 2: Right, and that's the crucial nuance here. While the initial
- 2:09Speaker 2: results are positive, the trial is limited by its small
- 2:13Speaker 2: sample size. The NASM study followed participants for a year.
- 2:17Speaker 2: during which one participant died 1979 days post-treatment. What does
- 2:23Speaker 2: that even mean in terms of direct causation or correlation
- 2:26Speaker 2: with the therapy?
- 2:27Speaker 1: Great question. The fact that the death was unconnected to
- 2:30Speaker 1: the treatment, according to the study, might sound reassuring, but
- 2:34Speaker 1: it still raises critical questions about long-term safety and the
- 2:38Speaker 1: risk-benefit ratio. We need more data, more follow-up studies to
- 2:42Speaker 1: truly understand what's happening in the long run.
- 2:44Speaker 2: Absolutely. The success in lowering LDL cholesterol is undeniable, but
- 2:50Speaker 2: the ethical and safety concerns can't be ignored. We are
- 2:53Speaker 2: talking about permanent genetic changes which could have unforeseen consequences.
- 2:59Speaker 2: How do you see this playing out in clinical practice
- 3:01Speaker 2: once it moves beyond the experimental stage?
- 3:04Speaker 1: Ethical considerations aside, this could indeed reshape how we approach
- 3:09Speaker 1: chronic conditions. If more robust and detailed follow-up, studies confirm
- 3:14Speaker 1: the safety and efficacy. the potential could be immense. But
- 3:18Speaker 1: for now, the focus needs to be on rigorous clinical
- 3:20Speaker 1: trials and extensive monitoring to ensure there are no hidden downsides.
- 3:25Speaker 2: That's a solid point. The NEJ-MIM study, while promising, is
- 3:30Speaker 2: just the beginning. The upcoming Phase 1b trial will be
- 3:34Speaker 2: crucial in addressing some of these uncertainties. For now, Connecticut
- 3:39Speaker 2: X310 remains a fascinating frontier in genetic medicine. but one
- 3:44Speaker 2: that requires careful navigation.
- 3:46Speaker 1: So, let's delve into the nitty-gritty of the ANKTL3 editing
- 3:50Speaker 1: process and the one-time treatment benefits. How exactly does CRISPR
- 3:55Speaker 1: work here to reduce LDL cholesterol levels?
- 3:58Speaker 2: Right, and that's the crucial nuance here. In the case
- 4:02Speaker 2: of CTX310, the CRISPR-Cas9 system is used to precisely target
- 4:07Speaker 2: the ANKTL3 gene in liver cells. Essentially, it's like using
- 4:12Speaker 2: molecular scissor technology to snip out a piece of the
- 4:15Speaker 2: gene's instruction set, reducing the protein production that contributes to
- 4:20Speaker 2: high LDL cholesterol.
- 4:21Speaker 1: Exactly. Which brings up an interesting contradiction. While the precise
- 4:26Speaker 1: nature of CRISPR is a game-changer, isn't there a risk
- 4:30Speaker 1: of off-target effects, potentially leading to unintended genetic editing?
- 4:34Speaker 2: Precisely. One of the key challenges is ensuring that the
- 4:38Speaker 2: CRISPR mechanism doesn't go rogue. In this study, the participants
- 4:42Speaker 2: were carefully selected to have high-risk lipid disorders that hadn't
- 4:46Speaker 2: responded to conventional treatments. This ensures a focused and manageable cohort,
- 4:51Speaker 2: but it still leaves us with a question about the
- 4:54Speaker 2: broader applicability of this one-time treatment. Absolutely. The reduction in
- 4:59Speaker 2: AIM-PTL3 levels is fascinating, but it also raises a lot
- 5:03Speaker 2: of ethical questions. How safe is this in the long run?
- 5:07Speaker 2: And as we look at the participants' selections, Those 15
- 5:10Speaker 2: subjects had to fit a very specific profile. What about
- 5:13Speaker 2: individuals with different lipid profiles or other underlying health conditions?
- 5:18Speaker 2: Could this treatment work for everyone or just for those
- 5:21Speaker 2: with high risk disorders?
- 5:23Speaker 1: That's a good point. The strategic participant selection was key.
- 5:28Speaker 1: The trial included 15 participants who had not responded to
- 5:32Speaker 1: conventional therapies. This suggests that for those with particularly stubborn cases,
- 5:38Speaker 1: This could be a viable, long-term solution. But what's the
- 5:42Speaker 1: likelihood of a treatment that works so well for one
- 5:45Speaker 1: set of individuals will work equally well for the average person?
- 5:49Speaker 2: Exactly. The NEGEM study is promising, but the Phase 1B
- 5:53Speaker 2: trial will be critical in answering these questions. We need
- 5:57Speaker 2: to see if these benefits can be replicated across a
- 6:00Speaker 2: larger and more diverse population. Plus … The ethical concerns
- 6:04Speaker 2: around gene editing and its long-term impacts can't be ignored.
- 6:08Speaker 2: It's a complex equation we are solving here, one that
- 6:12Speaker 2: touches on both medical and moral territory.
- 6:14Speaker 1: Indeed, the one-time nature of the treatment is appealing for
- 6:18Speaker 1: its simplicity and reduced risk of side effects compared to
- 6:22Speaker 1: ongoing medication. But the trade-offs in terms of precision and
- 6:26Speaker 1: potential side effects need to be carefully weighed. The NAJM
- 6:31Speaker 1: study opened the door. but the real-world application will depend
- 6:35Speaker 1: on extensive follow-up and monitoring.
- 6:37Speaker 2: That's it. And that's why the upcoming Phase 1B trial
- 6:40Speaker 2: is so important. It will help us understand if the
- 6:43Speaker 2: initial findings hold up and whether the treatment could be
- 6:46Speaker 2: safely and effectively extended to a broader patient population. The
- 6:50Speaker 2: potential is immense, but the path to widespread use is
- 6:53Speaker 2: fraught with both opportunity and risk.
- 6:55Speaker 1: Alright, let's dive into the heart of the matter with
- 6:58Speaker 1: genetic editing. Off-target effects are a significant concern in these treatments.
- 7:04Speaker 1: Can you explain how that might impact patient outcomes? Thomas?
- 7:08Speaker 2: Absolutely, Rachel. Off-target effects are indeed a double-edged sword. For example,
- 7:14Speaker 2: if the CRISPR technology mistakenly hits a different part of
- 7:17Speaker 2: the genome, it could cause unintended mutations. Think of it
- 7:22Speaker 2: like trying to hit a specific note on a piano.
- 7:24Speaker 2: What if the hammer misses and hits the next key?
- 7:27Speaker 2: It's like playing a wrong tune.
- 7:29Speaker 1: That's a great analogy. And what about the sustainability of
- 7:33Speaker 1: these changes? Will the genetic edits really stick over the
- 7:37Speaker 1: long term? Or could they be temporary?
- 7:40Speaker 2: It's a fascinating question. Currently, the data from CTX310 shows
- 7:45Speaker 2: promising results, but it's still too early to conclude if
- 7:49Speaker 2: the genetic changes will be permanent. Some patients might experience
- 7:53Speaker 2: long-term benefits while others might see their lipid levels increase again.
- 7:57Speaker 2: We need more longitudinal studies to truly understand the durability
- 8:01Speaker 2: of these edits.
- 8:02Speaker 1: Right, and that's the crucial nuance here. It's not just
- 8:05Speaker 1: about the immediate effects, but the long-term play. Now, let's
- 8:10Speaker 1: talk about applicability. The Cleveland Clinic's trial seems promising, but
- 8:15Speaker 1: can these treatments be adapted to diverse patient groups?
- 8:18Speaker 2: Great point, Rachel. That's where the complexity really lies. Different
- 8:23Speaker 2: people have different genetic makeups, and what works for one
- 8:26Speaker 2: group might not work for another. For instance, ANG-PTL3 levels
- 8:30Speaker 2: can vary quite a bit between individuals, so we need
- 8:33Speaker 2: to carefully tailor these treatments to fit various genetic profiles.
- 8:37Speaker 1: Exactly. Which brings up an interesting contradiction. On one hand,
- 8:42Speaker 1: the precision of CRISPR seems to offer a personalized medicine approach.
- 8:47Speaker 1: On the other hand, the variability among patients means we
- 8:50Speaker 1: might need a more generalized solution, that doesn't rely on
- 8:53Speaker 1: specific genetic markers.
- 8:55Speaker 2: That's wild when you look at the raw numbers. To
- 8:58Speaker 2: raise a risk that these treatments, while advanced, might end
- 9:01Speaker 2: up being too specific to a particular subgroup. This could
- 9:05Speaker 2: limit their widespread adoption in populations with more diverse genetic backgrounds.
- 9:09Speaker 1: Wait, but how does that actually play out in practice?
- 9:13Speaker 1: For example, what would be the impact if a treatment
- 9:16Speaker 1: works well in a small genetically homogeneous group, but fails
- 9:20Speaker 1: in a larger, more heterogeneous population.
- 9:23Speaker 2: Well, the practical implications could be significant. Imagine a treatment
- 9:28Speaker 2: that works wonders for a select few but falters in others.
- 9:33Speaker 2: It could lead to a situation where different communities get
- 9:36Speaker 2: different levels of care based on their genetic makeup. This
- 9:41Speaker 2: raises questions about equity and how we distribute these technologies.
- 9:45Speaker 1: That's a really important ethical consideration. It gets us into
- 9:49Speaker 1: questions about whether genetic editing should only be available to
- 9:52Speaker 1: specific groups, or if Terry's a need to find a
- 9:56Speaker 1: way to universalize these benefits.
- 9:58Speaker 2: Exactly. The debate around genetic editing is multifaceted. While the
- 10:03Speaker 2: technology holds immense promise, we need to navigate the complex
- 10:06Speaker 2: landscape of safety, ethics, and applicability. The Phase 1B trial
- 10:11Speaker 2: is going to be crucial in shedding light on these issues.
- 10:14Speaker 1: Speaking of the ongoing Phase 1B trials, we have got
- 10:18Speaker 1: a lot of ground to cover. Let's start with what
- 10:21Speaker 1: the lead researchers had to say about the continued study.
- 10:24Speaker 2: Absolutely. The Phase 1b trial is crucial because it will
- 10:28Speaker 2: provide more data, particularly on safety and long-term effects. According
- 10:33Speaker 2: to Dr. Laffin, the leading researcher, they are particularly focused
- 10:38Speaker 2: on gathering safety data in a larger, more diverse population.
- 10:41Speaker 1: Right. And that's the crucial nuance here, in their paper. Dr.
- 10:45Speaker 1: Laffin and colleagues, note that while the initial Phase 1a
- 10:49Speaker 1: results are promising, A broader trial is essential to ensure
- 10:53Speaker 1: the treatment is safe and effective for a wider range
- 10:56Speaker 1: of patients.
- 10:57Speaker 2: Exactly. Those are the kinds of pragmatic concerns that make
- 11:00Speaker 2: Phase 1B so important. For instance, they are looking closely
- 11:05Speaker 2: at potential side effects. One of the key quotes from
- 11:08Speaker 2: their report is, That's a key point.
- 11:18Speaker 1: The lead researcher also mentions the challenge of long-term safety.
- 11:22Speaker 1: Let's dive into that. Dr. Laffin states, long-term monitoring is
- 11:27Speaker 1: essential to determine the durability of the genetic change and
- 11:30Speaker 1: the absence of any adverse effects.
- 11:33Speaker 2: Right. And this brings up an interesting contradiction. While the
- 11:37Speaker 2: initial trials show significant reductions in LDL cholesterol, Therese still
- 11:42Speaker 2: concern about the potential for long-term complications. This is why
- 11:47Speaker 2: they are expanding the trial to include more participants.
- 11:50Speaker 1: Exactly. Which brings up an interesting contradiction, Thomas. The balance
- 11:55Speaker 1: between safety and therapeutic efficacy is often tough to maintain
- 11:59Speaker 1: in these pioneering treatments. Dr. Laffin notes, we need to
- 12:03Speaker 1: carefully weigh the benefits of the treatment against the unknowns
- 12:06Speaker 1: of long-term safety. That's a smart approach, and it gets
- 12:09Speaker 1: us to the broader implications for gene therapy in cardiology. Dr.
- 12:14Speaker 1: Laffin and his team are optimistic. but they also recognize
- 12:18Speaker 1: the need for more research. Their closing statement is quite telling.
- 12:22Speaker 1: The results of this trial provide a unique opportunity to
- 12:25Speaker 1: explore the potential of one-time, durable genetic changes in the
- 12:28Speaker 1: treatment of cardiovascular diseases.
- 12:30Speaker 2: Exactly. It's a fascinating area. The future of gene therapy
- 12:35Speaker 2: and cardiology could hinge on these kinds of trials, and
- 12:38Speaker 2: it raises questions about how we roll out such treatments.
- 12:42Speaker 2: Universal Access, for instance, could be a challenge if the
- 12:45Speaker 2: therapy ends up being very expensive or limited to specific
- 12:49Speaker 2: patient groups.
- 12:50Speaker 1: Right. The ethical considerations are immense.
- 12:53Speaker 2: Dr.
- 12:53Speaker 1: Laffin's team is working to address these issues, but it's
- 12:57Speaker 1: clear that a lot more research and discussion are needed.
- 13:00Speaker 1: In the meantime, the ongoing Phase 1B trial is setting
- 13:04Speaker 1: the stage for what could be a groundbreaking shift and
- 13:07Speaker 1: how we treat heart disease.
- 13:08Speaker 2: It's fascinating how far we have come, but also unsettling
- 13:12Speaker 2: to realize that we are standing on the threshold of
- 13:14Speaker 2: revolutionary changes. The CRISPR-based treatments like CTX310 are game changers,
- 13:23Speaker 2: but they come with a host of unresolved questions that
- 13:26Speaker 2: we can't afford to ignore.
- 13:28Speaker 1: Absolutely. The technology's potential is mind-blowing, but so are the
- 13:33Speaker 1: ethical and safety concerns. Take, for example, the off-target effects.
- 13:39Speaker 1: We need to ensure that these one-time treatments don't inadvertently
- 13:43Speaker 1: trigger other unpredictable genetic changes.
- 13:46Speaker 2: Exactly. That's the big scare. What if we are only
- 13:49Speaker 2: seeing the tip of the iceberg? We know that CRISPR
- 13:52Speaker 2: can be incredibly precise, but mistakes do happen, and they
- 13:56Speaker 2: can have lasting impacts. That's where longitudinal studies come in.
- 14:00Speaker 2: We need to monitor patients for years to ensure there
- 14:04Speaker 2: are no unforeseen consequences.
- 14:06Speaker 1: And the economic angle adds another layer of complexity. If
- 14:10Speaker 1: CRISPR-based treatments become the standard, who will have access to them?
- 14:14Speaker 1: High costs could create a significant divide, limiting these benefits
- 14:18Speaker 1: to only those who can afford it. Universal health care
- 14:22Speaker 1: might be essential to ensure equitable distribution.
- 14:25Speaker 2: Universal access is definitely a challenge, but let's not lose
- 14:28Speaker 2: sight of the positive. The Phase 1B trial is already
- 14:32Speaker 2: showing reductions in LDL cholesterol that could greatly impact heart
- 14:36Speaker 2: disease risk. It's clear that the benefits are real, and
- 14:39Speaker 2: they could save countless lives. The trick is figuring out
- 14:42Speaker 2: how to manage both the risks and the rewards. Right.
- 14:46Speaker 1: It's that balance we need to strike. Ethical committees, more
- 14:49Speaker 1: robust testing protocols, and stringent regulatory frameworks are essential moving forward.
- 14:56Speaker 1: We can't rush this. It's a complex landscape. and every
- 15:00Speaker 1: step must be carefully considered. Agreed.
- 15:02Speaker 2: And let's not forget the importance of transparency and public education.
- 15:07Speaker 2: People need to understand what CRISPR is, how it works,
- 15:10Speaker 2: and the potential pros and cons. That way, they can
- 15:13Speaker 2: make informed decisions about their health and give us the
- 15:16Speaker 2: social consensus we need for widespread adoption.
- 15:19Speaker 1: Exactly. The ongoing trials will be crucial. We need clear
- 15:23Speaker 1: data and real, world outcomes to push this forward. As
- 15:27Speaker 1: it stands, the results from the Cleveland Clinic are promising.
- 15:31Speaker 1: But they are just the beginning. Phase 1B and beyond
- 15:36Speaker 1: will provide the deeper insights we need to address the
- 15:39Speaker 1: ethical and safety concerns head.
- 15:42Speaker 2: On. And to raise the broader issue of public trust.
- 15:46Speaker 2: We have seen how quickly attitudes can shift once the
- 15:49Speaker 2: reality of gene editing hits home. We need to build trust.
- 15:53Speaker 2: not just through robust science, but through open and honest dialogue.
- 15:58Speaker 1: That's the true test, Thomas. Can we navigate these complex
- 16:02Speaker 1: waters with the right mix of science and social awareness?
- 16:06Speaker 1: The future of gene therapy is in our hands, and
- 16:09Speaker 1: it starts with making the right decisions now. That brings
- 16:12Speaker 1: us to the end of today's episode. Thank you so
- 16:15Speaker 1: much for spending part of your day with me. If
- 16:17Speaker 1: you found this episode's tips helpful and want to make
- 16:20Speaker 1: sure you don't miss the next conversation, Please take a
- 16:23Speaker 1: quick second to hit that subscribe or follow button on
- 16:26Speaker 1: whatever platform you are listening on. It's a completely free
- 16:29Speaker 1: way to support the show and helps more people find us.
- 16:33Speaker 1: This podcast is independently produced, so if you are ever
- 16:36Speaker 1: in a position where you would like to help keep
- 16:38Speaker 1: it running, we do accept small donations. You can find
- 16:42Speaker 1: a link right in the episode description below to buy
- 16:44Speaker 1: us a coffee or contribute what you can. Every bit
- 16:49Speaker 1: genuinely helps. Take care of yourself. Stay balanced. And we
- 16:53Speaker 1: will talk again soon.